Skip to NavigationSkip to content

Business Services

Verona Pharma appoints Novartis Gene Therapies VP Lisa Deschamps to its board

Published on: 02/03/21

Verona Pharma has appointed Lisa Deschamps, Senior Vice President and Chief Business Officer of Novartis Gene Therapies, as Non-Executive Director on their board.

Abivax appoints Dr Sophie Biguenet as Chief Medical Officer

Published on: 02/03/21

Clinical-stage biotechnology company Abivax has appointed Dr Sophie Biguenet as Chief Medical Officer.

Dr Biguenet brings 25 years of experience in academia and in the biopharmaceutical industry to the role, with an extensive track record in international clinical development, leading to the successful registration of several new drug products across various treatment areas.

MAPs during a global pandemic

Published on 26/02/21 at 12:39pm

Early and managed access programmes provide opportunities for patients to get the treatments they need faster - but the COVID-19 pandemic has taught us that the balance between efficacy and speed in the approval and rollout of medicines can be a treacherous pathway, Jack Goddard writes

How COVID-19 has changed pharmacovigilance

Published on 26/02/21 at 12:08pm

The race to provide vaccines and treatments for coronavirus has seen a number of COVID-19 drugs reach the market in record time. Darcy Jimenez explores how drug safety can be best ensured during this time, and how the pandemic has catalysed innovation in the area

In the months since the coronavirus pandemic began, a number of COVID-19 medicines have been made available to the public at faster rate than would usually be possible, as drug regulators’ approval processes have been expedited in response to the demand.

Exscientia appoints Moelis & Company COO Elizabeth Crain to Board of Directors

Published on: 10/02/21

AI-driven pharma-tech company Exscientia has appointed Elizabeth Crain to their Board of Directors.

Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board

Published on: 04/02/21

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has appointed Professor Mark Wilcox to its Scientific Advisory Board (SAB).

Raremark appoints Caroline O’Connor as CCO

Published on: 04/02/21

Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer.

Previously holding the position of Raremark’s Senior Vice President of Business Development, O’Connor will now take ownership of the company’s commercial focus and play a key role in growing its presence in the pharma industry.

Prior to joining the company, O’Connor’s focus was on eClinical technology, combined with establishing value and driving revenue growth from real-world evidence and digital patient support programmes in the post-approval setting.

Scenic Biotech appoints Dr Philippe Dro as Chairman

Published on: 02/02/21

Scenic Biotech has announced the appointment of Dr Philippe Dro as its independent Chairman. Dr Dro replaces Dr Ulrich Grau, who retires from the Board of Directors.

Swiss-based Dr Dro is trained in industrial pharmacy and finance. He has built a successful career in the European biotech and medtech sectors, serving on the boards of several start-ups and scaleups, initiating and executing notable strategic transactions. Alongside his role as Chairman of Scenic, he also serves as Chairman of Luciole Medical.

How COVID-19 has affected the oncology drugs market

Published on 25/01/21 at 04:01pm

In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the cancer drugs market – but not every change has necessarily been for the worse. Darcy Jimenez explores how the difficulties caused by the coronavirus crisis could improve drugs research, and speaks to major players about how they’ve adapted during this time

Raremark appoints Nicki Grundy as CFO

Published on: 20/01/21

Raremark, a global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer.

As a key member of Raremark’s senior leadership team, Grundy will take the lead on the company’s financial vision, strategic financial planning, and compliance.

Grundy has over 20 years of experience driving growth in businesses including CrownBio, Exco InTouch, and most recently Peppermint Technology, a legal software company.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches